PolyPid Passes Fourth Consecutive GMP Inspection, Advances D-PLEX₁₀₀ Toward 2026 NDA Submission
Key Insights
PolyPid successfully completed its fourth consecutive Good Manufacturing Practice inspection by the Israeli Ministry of Health (search), confirming commercial manufacturing readiness for D-PLEX₁₀₀ (search).
The inspection validates the company's quality systems under EU-Israel regulatory equivalence, meeting standards for commercial production in European markets.
D-PLEX₁₀₀ (search) demonstrated a statistically significant 58% relative risk reduction in surgical site infections (search) in Phase 3 SHIELD II trial for abdominal colorectal surgery.
PolyPid Ltd. (Nasdaq: PYPD) announced the successful completion of a routine Good Manufacturing Practice (GMP) inspection by the Israeli Ministry of Health (search), marking the fourth consecutive successful inspection of the company's manufacturing facility. The inspection, concluded earlier this week, advances the late-stage biopharma company toward commercial manufacturing readiness for its lead product candidate D-PLEX₁₀₀ (search).
The Israeli Ministry of Health (search) operates under the EU-Israel Agreement on Conformity Assessment and Acceptance (ACAA) framework, whereby European regulatory authorities rely on these inspections for EU GMP compliance certification. This regulatory equivalence confirms that PolyPid's manufacturing facility meets the standards required for commercial production in the European market.
Manufacturing Readiness Validated
"Successfully completing this inspection demonstrates our consistent adherence to international GMP standards and validates our quality systems for commercial-scale manufacturing," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "As we advance toward our planned New Drug Application (NDA) submission for D-PLEX₁₀₀ (search) in early 2026, this inspection serves as crucial real-world preparation for the U.S. Food and Drug Administration (FDA) facility inspection that will follow."
The inspection comprehensively evaluated PolyPid's quality systems, manufacturing processes, and facility operations, confirming the company's readiness to support commercial production of D-PLEX₁₀₀ (search) following regulatory approvals. The milestone reinforces PolyPid's path to commercialization as the company prepares for potential market entry in both U.S. and European markets.
D-PLEX₁₀₀ Clinical Success
D-PLEX₁₀₀ (search), PolyPid's lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent surgical site infections (search) (SSIs). The treatment utilizes the company's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, which pairs with Active Pharmaceutical Ingredients to enable prolonged and continuous release of the broad-spectrum antibiotic doxycycline.
Following administration into the surgical site, D-PLEX₁₀₀ (search) results in high local concentration of doxycycline for a period of 30 days for SSI prevention, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site.
D-PLEX₁₀₀ (search) recently demonstrated positive results in the Phase 3 SHIELD II trial, achieving a statistically significant 58% relative risk reduction in SSI incidence following abdominal colorectal surgery with large incisions. The product received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery.
Regulatory Timeline
With positive Phase 3 SHIELD II results in hand, Akselbrad noted that confirming manufacturing readiness represents another step toward bringing D-PLEX₁₀₀ (search) to patients. The company expects to submit its New Drug Application for D-PLEX₁₀₀ for the prevention of abdominal colorectal surgical site infections (search) in early 2026.
PolyPid's proprietary PLEX technology enables precise delivery of drugs at optimal release rates over durations ranging from several days to months through locally administered, controlled, prolonged-release therapeutics. In addition to D-PLEX₁₀₀ (search), the company maintains an innovative pipeline in oncology, obesity and diabetes.